Damaged helical collagen (DHC)

Damaged helical collagen refers to collagen molecules within the extracellular matrix (ECM) that have lost their native triple-helical structure due to mechanical injury, enzymatic degradation by matrix metalloproteinases (MMPs), or thermal denaturation. While healthy collagen is highly stable and resistant to non-specific binding, damaged or denatured collagen exposes cryptic binding sites and single-stranded peptide sequences that are absent in intact tissue. This structural transition serves as a specific hallmark of pathological remodeling in various conditions, including invasive tumors, fibrotic organs, and inflamed joints. In the context of drug development, damaged helical collagen is utilized as a highly selective docking site for therapeutic and diagnostic agents. Collagen hybridizing peptides (CHPs) are the primary class of molecules designed to target this state, as they can reform the triple helix specifically with the unfolded collagen strands. This targeting strategy enables the localized delivery of chemotherapeutics to the tumor microenvironment or the high-resolution imaging of active disease progression in musculoskeletal and cardiovascular disorders. By focusing on the physical state of the ECM rather than specific cell-surface receptors, this approach offers a broad-spectrum method for addressing diverse diseases characterized by excessive tissue turnover.

Other names

Denatured collagenDegraded collagenUnfolded collagenGelatinRemodeled collagenProteolyzed collagen

Drugs or imaging agents typically utilize collagen hybridizing peptides (CHPs) that specifically recognize and bind to the unfolded or degraded collagen strands through hydrogen-bonded triple helix formation, allowing for targeted delivery or visualization of sites with active extracellular matrix remodeling.